Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month…
15/04/2021 - 5 minutes
Mark Zipkin
Mark Zipkin is a freelance writer and consultant for the biotech and pharma industry, and a Central Operations Analyst for safety app Citizen. He was previously a staff writer at BioCentury, and has worked for SpringerNature journals including Nature Biotechnology and Nature Neuroscience. Mark lives in New Jersey with his wife and three children. Follow Mark on Twitter @MarkZipkin.
Have European Investors Missed the Exosome ‘Gold Rush’?
When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled…
01/04/2021 - 5 minutes
